AKT1 and amyotrophic lateral sclerosis: One of only two FDA-approved ALS therapeutics, edaravone, has been shown to increase RET and GFRα1 protein levels, and increase AKT and ERK1/2 activation in MNs derived from ALS-patient iPSCs [24].